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patients with type 2 diabetes mellitus (T2DM). This study explored the association 
of race/ethnicity and gender with complications severity, HRU, and costs among 
Medicare Advantage patients. Methods: A retrospective cohort study was per-
formed using medical and pharmacy claims of 333,576 Medicare members enrolled 
from 1/1/2010 to 12/31/2011, aged 18 to 89, and with ≥ 1 medical claim with primary 
diagnosis or ≥ 2 medical claims with secondary diagnosis of T2DM (ICD-9-CM 250.
x0 or 250.x2). Complications severity was assessed with the Diabetes Complications 
Severity Index, with scores of 0 (no complications) through 5+ (five or more). HRU 
was reported by mean (standard deviation [SD]) number of outpatient, inpatient, 
and emergency room [ER] visits. Costs were reported as means (SD) of medical, 
pharmacy and total health care costs evaluated. Associations of race/ethnicity and 
gender with the three outcomes were evaluated using generalized linear regression 
models. Results: The sample was older (70.81 ±8.8 years) and 80% White. Being 
Hispanic, Black, or male was associated with a higher prevalence of more severe 
T2DM complications; this disparity was more pronounced among females, with 
the odds of having more severe complications being higher for Hispanic and Black 
females compared to White females (Hispanic v. White odds ratio [OR], 1.40; 95% 
confidence interval [CI], 1.32-1.48), and (Black v. White OR, 1.22; 95% CI, 1.19-1.25). 
Regardless of gender, Blacks had more ER visits than Whites. Whites, particularly 
females, incurred the highest total annual health care costs, (White female costs: 
$13,086; 95% CI, $12,935-$13,240) vs. (Hispanic female costs: $10,732; 95% CI, $10,406-
$11,067). ConClusions: Racial/ethnic and gender differences exist in certain T2DM 
clinical and economic outcomes. Following these specific patients’ progress more 
closely may prevent or delay complications and decrease long term costs
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objeCtives: Eclampsia remains a major cause of maternal morbidity and mortal-
ity worldwide. In underdeveloped countries, the mortality rate is even higher due 
to the poor access to the health care, socio-economical problems and the cost of 
the treatment involved therein. To find out the trends and maternal outcomes in 
eclampsia in the region, a study was carried in a tertiary care unit i.e. Department 
of Gynaecology/Obstetrics, Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan, 
with the collaboration of Department of Pharmacology, King Saud University, Saudi 
Arabia. Methods: A total no. of 67 (n = 67) patients presented with eclampsia 
were assessed for maternal morbidity and mortality outcomes during the period 
of 6 months. A prospective study using a cross- sectional descriptive design was 
used. The patients were evaluated for various parameters that included biologi-
cal aging, type of complications, literacy level, socio-economical status, and par-
ity. Results: The calculated mean age of the patients was 25.69 ± 8.42 years. The 
incidence was found to be higher in the extremes of the reproductive life (bimodal 
variation), and during ante partum stage (55.2%) followed by postpartum (31.3%) 
and intrapartum period (13.4%). Among the patients examined, 44.8% were found 
with no formal education, 25.4% having primary education only, and 74.6% patients 
belonging to the lower socio-economic class. The incidence of eclampsia was higher 
in nulliparous women (58.2%) as compared to multiparous (31.3%) and grand mul-
tiparous women (10.4%). The overall complication to non-complication ratio was 
found to be 38.8% to 61.2%, with morbidity and mortality rate of 38.8 % and 13.4%, 
respectively. ConClusions: Keeping these finding in views, we may conclude that 
poor education, lack of effective health policies, and socioeconomic problems may 
contribute significantly to the morbidity and mortality associated with eclampsia 
in under developed regions.
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objeCtives: To conduct a thorough search of medical literature investigating 
the prevalence of cardiovascular comorbidities and its impact on health care 
costs, quality of life, and mortality among patients with type 2 diabetes mellitus 
(T2DM). Methods: Keywords and Medical Subject Headings were used to perform 
a search using MEDLINE, Cochrane, CINHAL Plus, and PsychINFO. Eligible studies 
were: published in English before June 2013, included cardiovascular or other 
comorbidities of T2DM, outcome researched was prevalence, economic burden, 
age of onset, quality of life or mortality of cardiovascular or other comorbidi-
ties, and the sample size was larger than 50. Results: Seventy-six studies and 
reports were used in this systematic review. Cardiovascular disease (CVD), includ-
ing hypertension, was the most prevalent complication of T2DM. Total health care 
costs of diabetic patients with CVD ranged from $10,450 to $14,414 per-person 
per-year in the United States. Quality of Life was found to be significantly lower 
in diabetes patients with cardiovascular complications, while mortality was found 
to be much higher than either illness alone. ConClusions: Prevalence of CVD 
is very high in T2DM patients with hypertension being the most prevalent. The 
additional cost burden due to CVD is also higher than any other comorbidity 
except End Stage Renal Disease (ESRD). Considering the much higher prevalence 
of CVD, compared with ESRD, increased cost due to CVD is likely to be higher than 
any other comorbidity at a population level. The quality of life was much lower in 
patients with CVD and diabetes, but not as low as in patients with comorbid pain-
ful neuropathy. Increased mortality was caused by the combination of diabetes and 
CVD. Cardiovascular complications in diabetes patients have a significant impact 
on the economic burden, quality of life, and the mortality rates. This research was 
funded by Bristol Myers Squibb.
(p-value < 0.0001). ConClusions: After adjusting for patient and hospital factors, 
hospital quality scores (both AMI and HF) were not strongly associated with the large 
amounts some hospitals charge beyond the standard reimbursement amount. The 
lack of strong associations suggests that either: (1) quality scores were not indica-
tors of hospital resource utilization, or (2) hospital charges were not driven by the 
expenses incurred as a result of providing high quality services, furthering the 
argument for increased cost transparency from health care providers.
Pcv130
treatMent PatternS of care for non-valvular atrial fibrilation 
PatientS at a national inStitute of care in Peru
Sanabria C.1, Cabrejos J.1, Guevara C.2, Olortegui A.2, Garrido Lecca S.3
1Universidad Nacional Mayor de San Marcos, Lima, Peru, 2Instituto Nacional Cardiovascular 
(INCOR) del Seguro Social de Salud del Perú, Lima, Peru, 3Bristol-Myers Squibb, Lima, Peru
objeCtives: To characterize treatment patterns and health care resource utilization 
among adults diagnosed with non-valvular atrial fibrillation (NVAF) at the Social 
Security system (EsSalud) in Peru. Methods: Observational retrospective study 
based on medical chart review from the National Cardiovascular Institute (INCOR). 
The study included patients over 18 years of age, with a confirmed diagnosis of 
NVAF based on physician diagnosis and ICD-10 code, treated at INCOR NVAF in 
2011, allowing for a minimum potential follow-up of one year. Clinical study enroll-
ment or AF patients with valvular origin were excluded. For each eligible patient, 
information on patient and disease characteristics, treatments received, clinical 
outcomes, and AF-related health care resource utilization was captured. Patients 
were randomly selected from an electronic database until the predetermined sam-
ple size of 83 eligible patients was met. Results: The study population median 
age was 68.8 years, 66.3% were male. CHADS2 distribution was: 0-7.2%, 1–18.1%, 
2-18.1%, 3–32.5%, 4–18.1%, 5–6 % and 6-0%. 89.2% of patients with NVAF received 
at least one prescription during follow-up; distribution according to drug classes: 
77.0% heart rate control, 75.7% antiplatelets, 60.8% antihypertensives, 50.3% vitamin 
K antagonists and 44.6% anti-arrhythmic. A median of 30.2 diagnostic tests includ-
ing electrocardiograms and INR tests were performed per patient (range: 1 - 144). 
Twenty-three percent of patients had at least one procedure with implantation of 
a pacemaker being the most frequent procedure, followed by AV node ablation. 
30% of patients were hospitalized at least once during the study follow up period. 
Median hospital stay was 12.6 days (range:1-115). ConClusions: NVAF manage-
ment is heterogeneous at INCOR, particularly for rhythm control, anticoagulation 
monitoring, and the utilization of anticoagulant therapy.
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objeCtives: Compare the comorbidities and health care resource utilization of 
chronic plaque psoriasis compared to a matched control cohort in a large, Canadian, 
real-world dataset. Methods: This was an observational, retrospective study of 
patients ≥ 18 years who, between 2008 and 2012 received a diagnosis of psoriasis 
and at least 1 treatment. Data were retrieved from the Southwestern Ontario (SWO) 
database, which is a representative primary care database of over 325,000 unique 
patient records in Ontario, Canada. Comorbidities and health resource utilization 
were recorded in the patient chart as per their health care provider. A matched 
control cohort was constructed based on age, gender and ethnicity. Differences 
between psoriasis and control groups were compared using paired and independent 
samples t-tests. Results: A total of 7,776 patients in the SWO database (n= 325,618) 
had a diagnosis of psoriasis and received at least 1 treatment between January 1, 
2008 and December 31, 2012. Of these, 85% had chronic plaque psoriasis. Over half 
of patients with chronic plaque psoriasis were diagnosed with hypertension (61%, 
similar in the control group), 11% had diabetes (vs 7% in control group), 4% had 
depression and/or anxiety disorders (vs 1%), 6% had insomnia (vs 1%). Thirty-two 
percent (32%) were overweight and 24% were obese (vs 27% and 19%, respectively). 
Patients with moderate to severe plaque psoriasis (28%) were more likely to visit 
their family physician than the control group (9 vs 3 visits per year, respectively). 
These patients missed more days of work than the control (11 vs 4, respectively) and 
recorded more work absences (2 vs 0.03 absence notes per year). ConClusions: 
Chronic plaque psoriasis is a significant health condition and is associated with 
higher rates of comorbidity and use of health services in Canada, especially in 
patients with a moderate-severe condition.
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objeCtives: Few studies have assessed racial/ethnic and gender differences in 
diabetes-related complications, health care resource utilization (HRU) and costs in 
